Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Home delivery company still not up to scratch

Healthcare at Home needs to create contingency plans to ensure it can deal with extra patients and complaints, GPhC says

A medicines home delivery company must undertake a "considerable amount of work" to address unresolved complaints about missed deliveries, the General Pharmaceutical Council (GPhC) has said. 


Healthcare at Home, which cares for more than 150,000 people across the UK, was reprimanded by the GPhC in April after an inspection found it was "insufficiently prepared" to deal with an increased number of patients. This had resulted in patients being left "confused and uncertain" about why their complaints about late and failed medicines deliveries were not being dealt with.


The company was ordered to remedy the situation by ensuring it had the capacity to deal with extra patients and complaints, but a further inspection three months later found that it needed to make "further progress" to create contingency plans, the GPhC said on Monday (September 1).


Although Healthcare at Home had made "some progress" in implementing the GPhC's recommendations, it still needed to eliminate the backlog of complaints and ensure the risks to patients caused by the late delivery of medicines were "recorded, monitored and acted on", the regulator said.


In its initial inspection in April, the GPhC found that Healthcare at Home was unprepared to deal with the "significant changes" of taking responsibility for an increased number of patients and transferring medicine distribution arrangements to another provider. The company's customer service team had been "overwhelmed" by complaints about late deliveries, some of which were left unresolved, it said.


The GPhC noted that, since its first inspection, the number of complaints had "stabilised" and there were more staff available to answer telephone calls from patients who had not received their medicines on time. The company had issued more guidance to staff to ensure they followed the correct processes and more data was being collected to assess risks, the GPhC said.


But the company still needed to ensure that any changes to its arrangements for delivering medicines to patients and its capacity to take on more patients or services was assessed "much more robustly", the regulator said. It recommended the company ensure patients could receive up-to-date information on their deliveries and that it create adequate contingency plans to maintain its service at times of increased workload.


The GPhC expected the company to implement the recommendations "swiftly" and would conduct a further inspection in two months to assess Healthcare at Home's progress, it added.





What do you think of the GPhC's verdict on Healthcare at Home?

We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD017258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel